Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Lymphoma, Mantle-Cell
  • Lymphoma, Non-Hodgkin
  • Protease Inhibitors
  • Pyrazines

abstract

  • These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.02.050

PubMed ID

  • 15613699

Additional Document Info

start page

  • 676

end page

  • 84

volume

  • 23

number

  • 4